Inventor · disambiguated record
David Frendewey
Also filed as: FRENDEWEY DAVID
55 granted patents·27 pending applications·1,509 citations·filing 2001–2025
99Inventor score
Files withREGENERON PHARMA72ALNYLAM PHARMACEUTICALS INC2ECONOMIDES ARIS N2FRENDEWEY DAVID2AUERBACH WOJTEK1
Top patents by PatentIndex Score
82 records- 0199US9546384B2Methods and compositions for the targeted modification of a mouse genomeREGENERON PHARMA·Filed 2014·Granted Jan 17, 2017·31 cites·26 claims
- 0299US9228208B2Methods and compositions for the targeted modification of a genomeREGENERON PHARMA·Filed 2014·Granted Jan 5, 2016·79 cites·24 claims
- 0398US10329582B2Genetic modification of ratsREGENERON PHARMA·Filed 2016·Granted Jun 25, 2019·25 cites·37 claims
- 0498US10208317B2Methods and compositions for the targeted modification of a mouse embryonic stem cell genomeREGENERON PHARMA·Filed 2016·Granted Feb 19, 2019·15 cites·61 claims
- 0598US8697851B2MiRNA-regulated differentiation-dependent self-deleting cassetteREGENERON PHARMA·Filed 2012·Granted Apr 15, 2014·91 cites·9 claims
- 0698US8354389B2miRNA-regulated differentiation-dependent self-deleting cassetteREGENERON PHARMA·Filed 2010·Granted Jan 15, 2013·56 cites·13 claims
- 0798US7659442B2Method for making homozygous genetic modificationsREGENERON PHARMA·Filed 2007·Granted Feb 9, 2010·239 cites·18 claims
- 0898US7576259B2Method for making genetic modificationsREGENERON PHARMA·Filed 2007·Granted Aug 18, 2009·236 cites·18 claims
- 0998US7294754B2Method for generating an animal homozygous for a genetic modificationREGENERON PHARMA·Filed 2005·Granted Nov 13, 2007·445 cites·15 claims
- 1097US9730434B2Methods and compositions for generating a mouseREGENERON PHARMA·Filed 2016·Granted Aug 15, 2017·11 cites·27 claims
- 1197US8759105B2Method for genetically modifying mouse embryonic stem cell by homologous recombinationECONOMIDES ARIS N·Filed 2007·Granted Jun 24, 2014·40 cites·10 claims
- 1296US10301646B2Nuclease-mediated targeting with large targeting vectorsREGENERON PHARMA·Filed 2017·Granted May 28, 2019·12 cites·28 claims
- 1396US10039269B2Methods and compositions for generating a mouseREGENERON PHARMA·Filed 2017·Granted Aug 7, 2018·10 cites·21 claims
- 1496US8846402B2Method for genetically modifying isolated non-human mammalian cell by homologous recombinationREGENERON PHARMA·Filed 2012·Granted Sep 30, 2014·17 cites·54 claims
- 1596US8518392B2Promoter-regulated differentiation-dependent self-deleting cassetteFRENDEWEY DAVID·Filed 2010·Granted Aug 27, 2013·57 cites·11 claims
- 1695US10711280B2Methods and compositions for the targeted modification of a mouse ES cell genomeREGENERON PHARMA·Filed 2018·Granted Jul 14, 2020·5 cites·69 claims
- 1795US9414575B2Methods and compositions for generating a mouseREGENERON PHARMA·Filed 2014·Granted Aug 16, 2016·12 cites·25 claims
- 1894US9834786B2Nuclease-mediated targeting with large targeting vectorsREGENERON PHARMA·Filed 2013·Granted Dec 5, 2017·13 cites·34 claims
- 1994US8946505B2Promoter-regulated differentiation-dependent self-deleting cassetteREGENERON PHARMA·Filed 2013·Granted Feb 3, 2015·10 cites·11 claims
- 2094US8946504B2Promoter-regulated differentiation-dependent self-deleting cassetteREGENERON PHARMA·Filed 2013·Granted Feb 3, 2015·10 cites·16 claims
- 2192US9267152B2MiRNA-regulated differentiation-dependent self-deleting cassetteREGENERON PHARMA·Filed 2015·Granted Feb 23, 2016·4 cites·29 claims
- 2291US10457960B2Methods and compositions for targeted genetic modification using paired guide RNAsREGENERON PHARMA·Filed 2015·Granted Oct 29, 2019·5 cites·53 claims
- 2391US10344299B2Compositions and methods for modifying cellsREGENERON PHARMA·Filed 2017·Granted Jul 9, 2019·3 cites·13 claims
- 2491US10106820B2Methods and compositions for modifying a targeted locusREGENERON PHARMA·Filed 2015·Granted Oct 23, 2018·6 cites·43 claims
- 2591US9902971B2Methods for producing a mouse XY embryonic (ES) cell line capable of producing a fertile XY female mouse in an F0 generationREGENERON PHARMA·Filed 2015·Granted Feb 27, 2018·5 cites·41 claims
- 2691US8816150B2Conditioned culture mediaPOUEYMIROU WILLIAM·Filed 2007·Granted Aug 26, 2014·14 cites·19 claims
- 2790US10793874B2Methods and compositions for targeted genetic modifications and methods of useREGENERON PHARMA·Filed 2018·Granted Oct 6, 2020·4 cites·13 claims
- 2890US9096870B2miRNA-regulated differentiation-dependent self-deleting cassetteREGENERON PHARMA·Filed 2014·Granted Aug 4, 2015·6 cites·13 claims
- 2989US12110502B2Models of tauopathyREGENERON PHARMA·Filed 2023·Granted Oct 8, 2024·1 cites·42 claims
- 3089US11845957B2Models of tauopathyREGENERON PHARMA·Filed 2020·Granted Dec 19, 2023·2 cites·51 claims
- 3189US10781453B2Non-human animals having a hexanucleotide repeat expansion in a C9ORF72 locusREGENERON PHARMA·Filed 2017·Granted Sep 22, 2020·6 cites·48 claims
- 3289US9655351B2Production of fertile XY female animals from XY ES cellsREGENERON PHARMA·Filed 2016·Granted May 23, 2017·3 cites·42 claims
- 3389US9410163B2Promoter-regulated differentiation-dependent self-deleting cassetteREGENERON PHARMA·Filed 2014·Granted Aug 9, 2016·3 cites·12 claims
- 3489US9398762B2Production of fertile XY female animals from XY ES cellsREGENERON PHARMA·Filed 2014·Granted Jul 26, 2016·7 cites·21 claims
- 3589US2024052365A1Methods and compositions for the targeted modification of a genomeREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 3688US10894965B2Genetic modification of ratsREGENERON PHARMA·Filed 2019·Granted Jan 19, 2021·2 cites·39 claims
- 3788US9149026B2Production of fertile XY animals from XY ES cellsAUERBACH WOJTEK·Filed 2011·Granted Oct 6, 2015·8 cites·9 claims
- 3887US9885058B2Production of fertile XY female mice from XY mouse ES cellsREGENERON PHARMA·Filed 2017·Granted Feb 6, 2018·2 cites·26 claims
- 3986US2024352489A1Methods and compositions for modifying a targeted locusREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 4085US10294494B2Methods and compositions for modifying a targeted locusREGENERON PHARMA·Filed 2017·Granted May 21, 2019·2 cites·43 claims
- 4185US9677129B2Method for detecting the replacement of an endogenous allele with a modified allele by homologous recombination in a mouse ES cellECONOMIDES ARIS N·Filed 2014·Granted Jun 13, 2017·3 cites·11 claims
- 4282US12391920B2Models of tauopathyREGENERON PHARMA·Filed 2024·Granted Aug 19, 2025·0 cites·27 claims
- 4382US12060571B2Methods and compositions for modifying a targeted locusREGENERON PHARMA·Filed 2019·Granted Aug 13, 2024·1 cites·49 claims
- 4482US10023916B2Markers of tumor cell response to anti-cancer therapyREGENERON PHARMA·Filed 2014·Granted Jul 17, 2018·5 cites·3 claims
- 4580US2023332185A1Methods and compositions for targeted genetic modification using paired guide rnasREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 4679US11697828B2Methods and compositions for targeted genetic modification using paired guide RNAsREGENERON PHARMA·Filed 2019·Granted Jul 11, 2023·1 cites·33 claims
- 4779US11021719B2Methods and compositions for assessing CRISPER/Cas-mediated disruption or excision and CRISPR/Cas-induced recombination with an exogenous donor nucleic acid in vivoREGENERON PHARMA·Filed 2018·Granted Jun 1, 2021·1 cites·30 claims
- 4877US2025280805A1Methods for producing antigen-binding proteins against foreign antigensREGENERON PHARMA·Filed 2025·Application pending·0 cites
- 4976US12065661B2Genetic modification of ratsREGENERON PHARMA·Filed 2020·Granted Aug 20, 2024·0 cites·21 claims
- 5076US11820997B2Methods and compositions for the targeted modification of a genomeREGENERON PHARMA·Filed 2020·Granted Nov 21, 2023·0 cites·73 claims
Showing the top 50 of 82 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when David Frendewey files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →